Skip to main content
SpringerLink
Log in

Potential unreliability of ALK variant allele frequency in the efficacy prediction of targeted therapy in NSCLC

  • Research Article
  • Published:
Frontiers of Medicine Aims and scope Submit manuscript

An Erratum to this article was published on 27 April 2024

This article has been updated

Abstract

Anaplastic lymphoma kinase (ALK) is the most common fusion gene involved in non-small cell lung cancer (NSCLC), and remarkable response has been achieved with the use of ALK tyrosine kinase inhibitors (ALK-TKIs). However, the clinical efficacy is highly variable. Pre-existing intratumoral heterogeneity (ITH) has been proven to contribute to the poor treatment response and the resistance to targeted therapies. In this work, we investigated whether the variant allele frequencies (VAFs) of ALK fusions can help assess ITH and predict targeted therapy efficacy. Through the application of next-generation sequencing (NGS), 7.2% (326/4548) of patients were detected to be ALK positive. On the basis of the adjusted VAF (adjVAF, VAF normalization for tumor purity) of four different threshold values (adjVAF < 50%, 40%, 30%, or 20%), the association of ALK subclonality with crizotinib efficacy was assessed. Nonetheless, no statistical association was observed between median progression-free survival (PFS) and ALK subclonality assessed by adjVAF, and a poor correlation of adjVAF with PFS was found among the 85 patients who received first-line crizotinib. Results suggest that the ALK VAF determined by hybrid capture-based NGS is probably unreliable for ITH assessment and targeted therapy efficacy prediction in NSCLC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Change history

References

  1. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno S, Ishikawa Y, Aburatani H, Niki T, Sohara Y, Sugiyama Y, Mano H. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448(7153): 561–566

    Article  CAS  PubMed  Google Scholar 

  2. Tian HX, Zhang XC, Yang JJ, Guo WB, Chen ZH, Wang Z, Wu YL. Clinical characteristics and sequence complexity of anaplastic lymphoma kinase gene fusions in Chinese lung cancer patients. Lung Cancer 2017; 114: 90–95

    Article  PubMed  Google Scholar 

  3. Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, Wu YL, Thomas M, O’Byrne KJ, Moro-Sibilot D, Camidge DR, Mok T, Hirsh V, Riely GJ, Iyer S, Tassell V, Polli A, Wilner KD, Jänne PA. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013; 368(25): 2385–2394

    Article  CAS  PubMed  Google Scholar 

  4. Camidge DR, Dziadziuszko R, Peters S, Mok T, Noe J, Nowicka M, Gadgeel SM, Cheema P, Pavlakis N, de Marinis F, Cho BC, Zhang L, Moro-Sibilot D, Liu T, Bordogna W, Balas B, Müller B, Shaw AT. Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non-small cell lung cancer in the global phase III ALEX study. J Thorac Oncol 2019; 14(7): 1233–1243

    Article  CAS  PubMed  Google Scholar 

  5. Shaw AT, Kim TM, Crinò L, Gridelli C, Kiura K, Liu G, Novello S, Bearz A, Gautschi O, Mok T, Nishio M, Scagliotti G, Spigel DR, Deudon S, Zheng C, Pantano S, Urban P, Massacesi C, Viraswami-Appanna K, Felip E. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2017; 18(7): 874–886

    Article  CAS  PubMed  Google Scholar 

  6. Camidge DR, Kim HR, Ahn MJ, Yang JCH, Han JY, Hochmair MJ, Lee KH, Delmonte A, García Campelo MR, Kim DW, Griesinger F, Felip E, Califano R, Spira A, Gettinger SN, Tiseo M, Lin HM, Gupta N, Hanley MJ, Ni Q, Zhang P, Popat S. Brigatinib versus crizotinib in advanced ALK inhibitor-naive ALK-positive non-small cell lung cancer: second interim analysis of the phase III ALTA-1L trial. J Clin Oncol 2020; 38(31): 3592–3603

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Solomon BJ, Besse B, Bauer TM, Felip E, Soo RA, Camidge DR, Chiari R, Bearz A, Lin CC, Gadgeel SM, Riely GJ, Tan EH, Seto T, James LP, Clancy JS, Abbattista A, Martini JF, Chen J, Peltz G, Thurm H, Ou SI, Shaw AT. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol 2018; 19(12): 1654–1667

    Article  CAS  PubMed  Google Scholar 

  8. Golding B, Luu A, Jones R, Viloria-Petit AM. The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC). Mol Cancer 2018; 17(1): 52

    Article  PubMed  PubMed Central  Google Scholar 

  9. Li Y, Zhang T, Zhang J, Li W, Yuan P, Xing P, Zhang Z, Chuai S, Li J, Ying J. Response to crizotinib in advanced ALK-rearranged non-small cell lung cancers with different ALK-fusion variants. Lung Cancer 2018; 118: 128–133

    Article  PubMed  Google Scholar 

  10. Song P, Zhang F, Li Y, Yang G, Li W, Ying J, Gao S. Concomitant TP53 mutations with response to crizotinib treatment in patients with ALK-rearranged non-small-cell lung cancer. Cancer Med 2019; 8(4): 1551–1557

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol 2018; 15(2): 81–94

    Article  CAS  PubMed  Google Scholar 

  12. Lim ZF, Ma PC. Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy. J Hematol Oncol 2019; 12(1): 134

    Article  PubMed  PubMed Central  Google Scholar 

  13. Goodwin S, McPherson JD, McCombie WR. Coming of age: ten years of next-generation sequencing technologies. Nat Rev Genet 2016; 17(6): 333–351

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Li W, Qiu T, Ling Y, Gao S, Ying J. Subjecting appropriate lung adenocarcinoma samples to next-generation sequencing-based molecular testing: challenges and possible solutions. Mol Oncol 2018; 12(5): 677–689

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Normanno N, Rachiglio AM, Lambiase M, Martinelli E, Fenizia F, Esposito C, Roma C, Troiani T, Rizzi D, Tatangelo F, Botti G, Maiello E, Colucci G, Ciardiello F; CAPRI-GOIM investigators. Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial. Ann Oncol 2015; 26(8): 1710–1714

    Article  CAS  PubMed  Google Scholar 

  16. Gieszer B, Megyesfalvi Z, Dulai V, Papay J, Kovalszky I, Timar J, Fillinger J, Harko T, Pipek O, Teglasi V, Regos E, Papp G, Szallasi Z, Laszlo V, Renyi-Vamos F, Galffy G, Bodor C, Dome B, Moldvay J. EGFR variant allele frequency predicts EGFR-TKI efficacy in lung adenocarcinoma: a multicenter study. Transl Lung Cancer Res 2021; 10(2): 662–674

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Li W, Guo L, Liu Y, Dong L, Yang L, Chen L, Liu K, Shao Y, Ying J. Potential unreliability of uncommon ALK, ROS1, and RET genomic breakpoints in predicting the efficacy of targeted therapy in NSCLC. J Thorac Oncol 2021; 16(3): 404–418

    Article  CAS  PubMed  Google Scholar 

  18. Li W, Qiu T, Guo L, Ying J. Major challenges related to tumor biological characteristics in accurate mutation detection of colorectal cancer by next-generation sequencing. Cancer Lett 2017;410:92–99

    Article  CAS  PubMed  Google Scholar 

  19. Li W, Zhang J, Guo L, Chuai S, Shan L, Ying J. Combinational analysis of FISH and immunohistochemistry reveals rare genomic events in ALK fusion patterns in NSCLC that responds to crizotinib treatment. J Thorac Oncol 2017; 12(1): 94–101

    Article  PubMed  Google Scholar 

  20. Ying J, Guo L, Qiu T, Shan L, Ling Y, Liu X, Lu N. Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma. Ann Oncol 2013; 24(10): 2589–2593

    Article  CAS  PubMed  Google Scholar 

  21. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45(2): 228–247

    Article  CAS  PubMed  Google Scholar 

  22. Camidge DR, Theodoro M, Maxson DA, Skokan M, O’Brien T, Lu X, Doebele RC, Barón AE, Varella-Garcia M. Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive nonsmall cell lung cancer. Cancer 2012; 118(18): 4486–4494

    Article  CAS  PubMed  Google Scholar 

  23. Camidge DR, Kono SA, Flacco A, Tan AC, Doebele RC, Zhou Q, Crino L, Franklin WA, Varella-Garcia M. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res 2010; 16(22): 5581–5590

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Li W, Zhang J, Wang Z, Li L, Ma J, Zhou X, Wang J, Liang Z, Ying J. Guidelines for clinical practice of ALK fusion detection in non-small-cell lung cancer: a proposal from the Chinese RATICAL study group. Journal of the National Cancer Center 2021; 1(4): 123–131

    Article  Google Scholar 

  25. Ilie MI, Bence C, Hofman V, Long-Mira E, Butori C, Bouhlel L, Lalvée S, Mouroux J, Poudenx M, Otto J, Marquette CH, Hofman P. Discrepancies between FISH and immunohistochemistry for assessment of the ALK status are associated with ALK ‘borderline’-positive rearrangements or a high copy number: a potential major issue for anti-ALK therapeutic strategies. Ann Oncol 2015; 26(1): 238–244

    Article  CAS  PubMed  Google Scholar 

  26. Wang H, Sun L, Sang Y, Yang X, Tian G, Wang Z, Fang J, Sun W, Zhou L, Jia L, Tsao MS, Shi H, Lin D. A study of ALK-positive pulmonary squamous-cell carcinoma: from diagnostic methodologies to clinical efficacy. Lung Cancer 2019; 130: 135–142

    Article  PubMed  Google Scholar 

  27. Benayed R, Offin M, Mullaney K, Sukhadia P, Rios K, Desmeules P, Ptashkin R, Won H, Chang J, Halpenny D, Schram AM, Rudin CM, Hyman DM, Arcila ME, Berger MF, Zehir A, Kris MG, Drilon A, Ladanyi M. High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no mitogenic driver alteration detected by DNA sequencing and low tumor mutation burden. Clin Cancer Res 2019; 25(15): 4712–4722

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Li W, Wan R, Guo L, Chang G, Jiang D, Meng L, Ying J. Reliability analysis of exonic-breakpoint fusions identified by DNA sequencing for predicting the efficacy of targeted therapy in non-small cell lung cancer. BMC Med 2022; 20(1): 160

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Raja R, Kuziora M, Brohawn PZ, Higgs BW, Gupta A, Dennis PA, Ranade K. Early reduction in ctDNA predicts survival in patients with lung and bladder cancer treated with durvalumab. Clin Cancer Res 2018; 24(24): 6212–6222

    Article  CAS  PubMed  Google Scholar 

  30. Li X, Cai W, Yang G, Su C, Ren S, Zhao C, Hu R, Chen X, Gao G, Guo Z, Li W, Zhou C, Hirsch FR. Comprehensive analysis of EGFR-mutant abundance and its effect on efficacy of EGFR TKIs in advanced NSCLC with EGFR mutations. J Thorac Oncol 2017; 12(9): 1388–1397

    Article  PubMed  Google Scholar 

  31. Beau-Faller M, Pencreach E, Leduc C, Blons H, Merlio JP, Bringuier PP, de Fraipont F, Escande F, Lemoine A, Ouafik L, Denis M, Hofman P, Lacave R, Melaabi S, Langlais A, Missy P, Morin F, Moro-Sibilot D, Barlesi F, Cadranel J; French Cooperative Thoracic Intergroup (IFCT). Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): results of the French cooperative thoracic intergroup (IFCT) biomarkers France project. Lung Cancer 2020; 140: 19–26

    Article  PubMed  Google Scholar 

  32. Elez E, Chianese C, Sanz-García E, Martinelli E, Noguerido A, Mancuso FM, Caratù G, Matito J, Grasselli J, Cardone C, Esposito Abate R, Martini G, Santos C, Macarulla T, Argilés G, Capdevila J, Garcia A, Mulet N, Maiello E, Normanno N, Jones F, Tabernero J, Ciardello F, Salazar R, Vivancos A. Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS-mutant metastatic colorectal cancer. Mol Oncol 2019; 13(9): 1827–1835

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Friedlaender A, Tsantoulis P, Chevallier M, De Vito C, Addeo A. The impact of variant allele frequency in EGFR mutated NSCLC patients on targeted therapy. Front Oncol 2021; 11: 644472

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. O’Kane GM, Liu G, Stockley TL, Shabir M, Zhang T, Law JH, Le LW, Sacher A, Shepherd FA, Bradbury PA, Leighl NB. The presence and variant allele fraction of EGFR mutations in ctDNA and development of resistance. Lung Cancer 2019; 131: 86–89

    Article  PubMed  Google Scholar 

  35. Head SR, Komori HK, LaMere SA, Whisenant T, Van Nieuwerburgh F, Salomon DR, Ordoukhanian P. Library construction for next-generation sequencing: overviews and challenges. Biotechniques 2014; 56(2): 61–64, 66, 68 passim

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Bruno R, Fontanini G. Next generation sequencing for gene fusion analysis in lung cancer: a literature review. Diagnostics (Basel) 2020; 10(8): 521

    Article  CAS  PubMed  Google Scholar 

  37. Vaclova T, Grazini U, Ward L, O’Neill D, Markovets A, Huang X, Chmielecki J, Hartmaier R, Thress KS, Smith PD, Barrett JC, Downward J, de Bruin EC. Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers. Nat Commun 2021; 12(1): 1780

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Zheng Q, Hong S, Huang Y, Zhao H, Yang Y, Hou X, Zhao Y, Ma Y, Zhou T, Zhang Y, Fang W, Zhang L. EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients. Clin Transl Med 2020; 9(1): 17

    Article  PubMed  PubMed Central  Google Scholar 

  39. Ai X, Cui J, Zhang J, Chen R, Lin W, Xie C, Liu A, Zhang J, Yang W, Hu X, Hu X, Zhao Q, Rao C, Zang YS, Ning R, Li P, Chang L, Yi X, Lu S. Clonal architecture of EGFR mutation predicts the efficacy of EGFR-tyrosine kinase inhibitors in advanced NSCLC: a prospective multicenter study (NCT03059641). Clin Cancer Res 2021; 27(3): 704–712

    Article  CAS  PubMed  Google Scholar 

  40. Bos MK, Nasserinejad K, Jansen MPHM, Angus L, Atmodimedjo PN, de Jonge E, Dinjens WNM, van Schaik RHN, Del Re M, Dubbink HJ, Sleijfer S, Martens JWM. Comparison of variant allele frequency and number of mutant molecules as units of measurement for circulating tumor DNA. Mol Oncol 2021; 15(1): 57–66

    Article  CAS  PubMed  Google Scholar 

  41. Bustamante Alvarez JG, Janse S, Owen DH, Kiourtsis S, Bertino EM, He K, Carbone DP, Otterson GA. Treatment of non-small-cell lung cancer based on circulating cell-free DNA and impact of variation allele frequency. Clin Lung Cancer 2021; 22(4): e519–e527

    Article  CAS  PubMed  Google Scholar 

  42. Hallberg B, Palmer RH. The role of the ALK receptor in cancer biology. Ann Oncol 2016; 27(Suppl 3): iii4–iii15

    Article  PubMed  Google Scholar 

  43. Qiu T, Zhang F, Li W, Guo L, Ying J. Concurrent presence of ALK rearrangement and MET mutation in lung adenocarcinoma. J Thorac Oncol 2019; 14(2): e42–e44

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by grants from the National Natural Science Foundation of China (No. 81802294) and the Beijing Hope Run Special Fund of Cancer Foundation of the People’s Republic of China (No. LC2019L04).

Author information

Author notes

  1. Wei Rao, Yutao Liu, and Yan Li equally contributed to this work.

Authors and Affiliations

  1. Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China

    Wei Rao, Yan Li, Lei Guo, Tian Qiu, Lin Dong, Jianming Ying & Weihua Li

  2. Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China

    Yutao Liu

Authors
  1. Wei Rao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yutao Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yan Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lei Guo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tian Qiu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Lin Dong
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jianming Ying
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Weihua Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Jianming Ying or Weihua Li.

Ethics declarations

Wei Rao, Yutao Liu, Yan Li, Lei Guo, Tian Qiu, Lin Dong, Jianming Ying, and Weihua Li declare that they have no conflict of interest. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000 (5). Informed consent was obtained from all patients for being included in the study.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rao, W., Liu, Y., Li, Y. et al. Potential unreliability of ALK variant allele frequency in the efficacy prediction of targeted therapy in NSCLC. Front. Med. 17, 493–502 (2023). https://doi.org/10.1007/s11684-022-0946-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11684-022-0946-x

Keywords

Search

Navigation